Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880191 | 0.80 | LMNA (0.54) | CA12CA1LMNAPOLBRXFP1 | |
| SCHEMBL3828974 | 0.76 | MAOA (0.51) | LMNAPOLBRXFP1NPC1RAB9A | |
| SCHEMBL2940952 | 0.74 | GAA (0.51) | LMNAPOLBRXFP1METAP1BRD9 | |
| SCHEMBL1534089 | 0.74 | NPC1 (0.58) | LMNAPOLBRXFP1BRD9NPC1 | |
| SCHEMBL2880194 | 0.74 | BRD9 (0.52) | CA12CA1ELANECTRB1LMNA | |
| SCHEMBL736662 | 0.74 | POLB (0.49) | CA12CA1LMNAPOLBRXFP1 | |
| SCHEMBL3784448 | 0.74 | GPR35 (0.50) | LMNAPOLBRXFP1METAP1BRD9 | |
| SCHEMBL1794452 | 0.74 | LMNA (0.49) | CA12CA1LMNAPOLBRXFP1 | |
| SCHEMBL18623980 | 0.73 | MEN1 (0.61) | POLBRXFP1RAB9AMEN1HTT | |
| SCHEMBL9291119 | 0.72 | METAP1 (0.50) | CA12CA1CA9PSMB8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423115-B9 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1423115-B1 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-7153867-B2 | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator | CELGENE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1423115-A4 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1423115-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | The Children's Medical Center Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2003-07-24 | — | — | US | disclosed |
| WO-2003014315-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | CA12 2171/4885CA1 2461/4885CA9 1113/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | CA12 2171/4885CA1 2461/4885CA9 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.